ABT - CIK 0000001800
The table below shows ABBOTT LABORATORIES's balance sheet by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $6.80B | $7.51B | $6.95B | $6.53B | $7.56B | $6.99B |
| Short-term investments | $492.00M | $222.00M | $331.00M | $312.00M | $230.00M | $232.00M |
| Receivables | $8.21B | $8.14B | $7.97B | $7.33B | $7.05B | $6.85B |
| Inventory | $6.99B | $6.71B | $6.95B | $6.64B | $6.81B | $6.81B |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| Total current assets |
| $25.51B |
| $24.84B |
| $24.47B |
| $23.15B |
| $23.80B |
| $23.12B |
| Property, plant & equipment | $12.38B | $11.50B | $11.39B | $10.93B | $10.62B | $10.23B |
| Goodwill | $35.22B | $23.97B | $23.95B | $23.36B | $23.66B | $23.31B |
| Total assets | $110.43B | $84.18B | $84.00B | $81.45B | $74.36B | $73.02B |
| Accounts payable | - | - | - | - | - | - |
| Total current liabilities | $18.38B | $14.58B | $13.44B | $13.00B | $14.90B | $13.76B |
| Long-term debt | $29.64B | $11.60B | $12.93B | $12.74B | $12.82B | $13.14B |
| Total liabilities | - | - | - | - | - | - |
| Retained earnings | $49.96B | $49.10B | $48.47B | $47.72B | $39.06B | $38.35B |
| Total equity | $52.06B | $50.95B | $50.56B | $48.81B | $39.80B | $39.32B |